6CM
PBYI icon

683 Capital Management’s Puma Biotechnology PBYI Stock Holding History

683 Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-55,005
Closed -$238K – 226
2023
Q4 		$238K Buy
+55,005
New +$182K 0.02% 168
2023
Q2 		– Sell
-36,500
Closed -$113K – 231
2023
Q1 		$113K Hold
36,500
– – 0.01% 225
2022
Q4 		$154K Buy
+36,500
New +$126K 0.01% 217

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

683 Capital Management's PBYI Position: Q1 2024 in Review

683 Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2024, closing a stake of 55,005 shares — an estimated $238K sold.

683 Capital Management first reported a position in PBYI in Q4 2022 and held it in 3 quarters. The position peaked at $238K in Q4 2023. 93 funds tracked by Wall St. Rank hold PBYI as of Q1 2024.

  • 683 Capital Management reported no remaining Puma Biotechnology position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 55,005 Puma Biotechnology shares in Q1 2024, an estimated $238K.
  • 683 Capital Management first reported a position in Puma Biotechnology in Q4 2022 and held it in 3 quarters.
  • 683 Capital Management's Puma Biotechnology position peaked at $238K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.